
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Riding the Employment Roller Coaster
almost 16 years ago
Quality Issues Reduxalmost 16 years ago
Riding the Employment Roller Coasteralmost 16 years ago
Pharma Faces New Political Landscapealmost 16 years ago
Report from Asiaalmost 16 years ago
A Catalyst for Green Synthesisalmost 16 years ago
Q&A with Coldstream CEO Larry Krankingalmost 16 years ago
In the Spotlight December 2010almost 16 years ago
Intellectual Property as the Foundation of Innovationalmost 16 years ago
Packagers for Hirealmost 16 years ago
Global Healthcare on the Ground: Differential Pricing




